Onco Actu du 9 décembre 2016

	3.1 Tabac
Australia’s plain cigarette packs get more support than expected [Reuters] Overall, support for the plain packaging rose, even among smokers, after it was introduced, compared to beforehand.
	3.1.1 Tabac - e-cigs
E-cigarettes are unsafe and ‘major public health concern’ for young people, warns US surgeon general [The Telegraph] His strongly-worded report said that serious action was needed to keep the products out of the hands of the nation's young people.
Know the Risks - E-cigarettes & Young People [Surgeon General] E-cigarettes are very popular with young people. Their use has grown dramatically in the last five years. Today, more high school students use e-cigarettes than regular cigarettes.
What Are the Risks for Teens Who Use E-Cigarettes? [The Atlantic] A new surgeon-general report calling vaping among young people a “major health concern” adds to a heated debate over whether the practice is safer than smoking.
	3.8 Prévention - Alimentation
Can cutting out chocolate really hold cancer at bay? [Cancer Research UK] As it stands, cutting out the odd chunk of chocolate won’t stop cancer from spreading. But if you dig a little deeper, the research behind today’s news is a lot more complex, and far more interesting, than the headlines make out.
	4. Dépistage, diagnostic et pronostic
Stem cell biomarker predicts leukemia patients' response to chemo [FierceBiotech] “With this core 17-gene score, we have shown we can rapidly measure risk in newly diagnosed AML patients.”
Craig Venter Used Own Posh Health Clinic To Diagnose His Cancer [Xconomy] Venter’s comments add to the debate about testing for cancer in otherwise healthy people.
	5.12 Immunothérapies
Personalised cancer vaccine may hold leukaemia at bay for longer [Cancer Research UK] By creating a personalised vaccine, the power of the immune system can be targeted against each patient's cancer. This could avoid some of the side effects of chemotherapy, said senior study author Professor David Avigan.
Too many stories ignore or underreport the harms of cancer immunotherapies. Here’s what the public needs to know. [HealthNewsReview] “I would like to see major newspapers make a commitment that when they write stories like this, two years or so from now they’ll check back with all the protagonists and see how they’re doing.”
	5.12.2 Immunothérapies - CAR-T
Immuno-oncology startup TCR2 promises to improve on CAR-T [FierceBiotech] T cells—and specifically chimeric antigen receptor (CAR-T) cells—are already being tested for their ability to tackle cancer, but TCR2 reckons its technology offers some improvements, including greater activity against solid tumors.
	5.2 Pharma
Celgene Pins Future on Decoding Successful Cancer Treatment [Bloomberg] Thalidomide was infamous for causing birth defects when Celgene Corp. transformed it into a blood-cancer treatment that brings in $7 billion a year. Trouble was, Celgene didn’t know exactly how the drug, Revlimid, worked.
	5.2.1 Pharma - Partenariats
Cancer Research Technology pioneer fund announces investment in blood cancer drugs [Cancer Research UK] The drugs will target a protein called B-Cell Lymphoma 6 (BCL6). It plays an important role in maintaining levels of antibody-secreting B-cells in the blood, and is an essential part of the body’s immune defences.
	5.3.4 Traitements - AMM (FDA, EMA)
European Commission Grants Conditional Marketing Approval for AbbVie's VENCLYXTO™ (venetoclax) Monotherapy for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia [AbbVie] VENCLYXTO™ (venetoclax) monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.
	5.5 ASCO
2017 Gastrointestinal Cancers Symposium Press Program to Highlight New Treatment Insights and Strategies [ASCO] Co-sponsors of the 2017 Gastrointestinal Cancers Symposium announced today three abstracts to be featured in the meeting’s official Press Program.
	5.7.2 SABCS-divers
New drug combination shows early promise for some breast cancer patients [Cancer Research UK] Finding a group of breast cancer patients who may benefit from everolimus is promising. But the study was in only 100 patients so larger trials are needed to confirm the findings.
	5.7.3 SABCS-AACR
Adding an Aromatase Inhibitor to Presurgery Treatment for HR-positive, HER2-positive Breast Cancer Provided No Additional Benefit [AACR] “At this point, we cannot recommend a change to the standard-of-care neoadjuvant treatment regimen for patients with HR-positive, HER2-positive breast cancer but, the combination was safe and well tolerated."
Phase II Trial of Presurgery Abemaciclib Treatment for Early-stage HR-positive, HER2-negative Breast Cancer Met Primary Endpoint [AACR] “Even though the results of this study were positive and promising, they will not change the standard of care because this was a proof of concept study,” said Hurvitz.
BELLE-3 Trial Meets Primary Endpoint of Progression-free Survival in Breast Cancer Patients [AACR] “The results of this trial are important for the scientific community because the trial shows the promising activity of a new class of anticancer agent, but in my opinion it is still premature to consider this agent as a new standard of care in the treatment of ER-positive advanced breast cancer patients.”
Adding Ibandronate to Hormone Therapy did Not Improve Outcomes For Postmenopausal Breast Cancer Patients [AACR] A favorable trend warrants longer follow-up for definitive evidence of benefit.
Radiation Therapy May Increase Complications in Breast Cancer Patients Receiving Implants [AACR] Patients who received autologous breast reconstruction after radiotherapy had no worsening of outcomes.
	6. Lutte contre les cancers
The Health Research Alliance Partners with ÜberResearch to Launch New Database [Digital Science] Today, the HRA has launched the HRA Reporter, a real time, searchable database of awards made by its 75 members. Currently, the HRA Reporter represents $8.9 billion in funding and over 31,000 separate grants from 2006 to the present.
	6.1 Observation
More foreign holidays will mean more skin cancer, scientists predict [The Guardian] That predicted 78% increase could also see the NHS’s costs of treating the disease rise to as much as £465m a year.
	6.10.1 Politiques (USA)
Destroying the FDA to save it? No, more like just destroying it. [Respectful Insolence] First the 21st Century Cures Act passes, weakening the FDA. Next, we’ll very likely end up with either a batshit nutty libertarian who doesn’t believe the FDA should require evidence of efficacy before approving drugs or a real, honest-to-goodness pharma shill as the next commissioner of the FDA.
Why Donald Trump's Putative FDA Pick Could Scare Pharma [Forbes] Pharmaceutical executives complain about the drug approval process, but usually don’t want to go anywhere close to a safety-only path. In practice, what they want is for the FDA to return their calls, for bureaucratic delays to be reduced, and to find the fastest and least expensive way to prove safety and efficacy.
Congressional Memo: Cures Act Gains Bipartisan Support That Eluded Obama Health Law [NY Times] . At a cost of $6.3 billion, the Cures Act is not small, but the Affordable Care Act cost hundreds of billions of dollars and affected every facet of medicine — from insurance coverage to delivery of care.
	6.6 Publications
Controversial impact factor gets a heavyweight rival [Nature] Although the index ranks journals with a formula that largely mimics the influential Journal Impact Factor (JIF), it covers twice as many journals — 22,000 to the JIF’s 11,000 — and its formula includes tweaks that produce some notably different results, including lower scores for some high-JIF journals.